Onasemnogene abeparvovec commonly linked to hepatotoxicity
27 Feb 2021
Hepatotoxicity is common after treatment with onasemnogene abeparvovec for spinal muscular atrophy, a recent study has found. Clinicians should anticipate and be ready to manage such adverse events, and be aware of any potential underlying conditions that could aggravate them.
The Role of Bilastine in Treating Paediatric Patients with Allergic Rhinoconjunctivitis and Urticaria
18 Feb 2021;
Bilastine is a second-generation antihistamine
that has proven efficacy in treating urticaria and both seasonal and perennial
It has been shown to have a rapid onset of
action with fast effect as early as 30 minutes, and prolonged duration of
effect of more than 24 hours in adults.2–4
In paediatric patients, the therapeutic dose was
identified based on the results of a pharmacokinetic study demonstrating that
bilastine 10 mg once daily in children aged 2 to 11 years offers the same systemic
exposure as 20 mg once daily in adults.